Aetna · Identified Aug 17, 2026Medium impact
Antepartum Fetal Surveillance (CPB 0088, reviewed 2026-08-05)
Aetna considers in-office and in-hospital antepartum fetal surveillance with non-stress tests, contraction stress tests, biophysical profiles, modified biophysical profiles, and umbilical artery and middle cerebral artery Doppler velocimetry medically necessary when the criteria in this policy are met. For most pregnancies at increased risk of stillbirth due to utero-placental insufficiency, testing is considered appropriate beginning at 32 to 34 weeks of gestation, and testing is medically necessary beginning at 26 weeks for pregnancies with multiple or particularly worrisome high-risk conditions. Repeat testing is medically necessary until delivery while the condition that prompted testing persists, and remote non-stress testing, uterine artery Doppler for risk assessment or screening, and all other indications not listed as medically necessary are considered experimental, investigational or unproven.